2013
DOI: 10.1016/j.jinorgbio.2013.04.005
|View full text |Cite
|
Sign up to set email alerts
|

Palladium(II) and platinum(II) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series with high cytotoxic activity in cisplatin resistant A2780cisR tumor cells and reduced toxicity

Abstract: Esta es la versión de autor del artículo publicado en: This is an author produced version of a paper published in:

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
36
0
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 73 publications
(40 citation statements)
references
References 36 publications
3
36
0
1
Order By: Relevance
“…In the past few decades, thiosemicarbazones (TSCs) and their metal complexes have been of interest to chemists and biologists because of their wide range of pharmacological effects [3][4][5][6]. Our previous work shows that copper(II) and nickel(II) complexes of TSCs bearing pyrrole unit have potential antitumor activity [5].…”
Section: Discussionmentioning
confidence: 99%
“…In the past few decades, thiosemicarbazones (TSCs) and their metal complexes have been of interest to chemists and biologists because of their wide range of pharmacological effects [3][4][5][6]. Our previous work shows that copper(II) and nickel(II) complexes of TSCs bearing pyrrole unit have potential antitumor activity [5].…”
Section: Discussionmentioning
confidence: 99%
“…Los compuestos de inclusión parcial de paladio (II) disminuyen en 50 % la proliferación de las células MCF-7 con concentraciones menores de 3 µM (figura 2, cuadro 1), las cuales son inferiores a las reportadas en la literatura científica, pues la CI 50 en la línea celular MCF-7 fluctúa entre 4,41 y 100 µM (9,31). La diferencia en la CI 50 puede estar asociada con la mayor solubilidad y estabilidad fisicoquímica producto de la inclusión en la beta-ciclodextrina del complejo de paladio (II) (24,32).…”
Section: Discussionunclassified
“…Therefore, there is increasing interest in structural modification of TSC derivatives, with the aim of improving the pharmaceutical profile of existing candidates or identifying novel derivatives. At present, the majority of studies have focused on the structure-activity association of TSCs bearing six-member heterocycles (9)(10)(11)(12)(13)(14). However, the antitumor effects and the underlying mechanisms of TSCs containing five-member heterocycles (15), particularly pyrrole, remain poorly understood.…”
Section: Introductionmentioning
confidence: 99%